The company announced plans to exit Medicare Advantage by 2027, focusing instead on Medicaid and Marketplace offerings as part of strategic realignment. Management highlighted ongoing challenges from Medicaid redetermination-related acuity shifts and high pharmacy costs.
Cyborg Score Rationale
Molina reported Q4 2025 adjusted loss of $2.75 per share, with stock plummeting 29.88% in premarket trading following the earnings shock. While management issued conservative 2026 guidance with premium revenue of $42 billion, the company faces margin pressures and strategic repositioning challenges.
Top Insights
Molina reported Q4 2025 adjusted loss of $2.75 per share, missing forecasts by 908.82% despite revenue of $11.38 billion exceeding expectations by 4.6%.
2026 guidance projects premium revenue of $42 billion, adjusted EPS of at least $5, flat Medicaid membership, and declining Marketplace enrollment.
Molina faces challenges following Q4 earnings miss and lowered price targets from major analysts, with concerns over Medicaid adjustments and rising medical costs persisting.
The stock has 19.50% upside potential based on analyst 12-month price targets.
Named Competitors
UnitedHealth — Largest US health insurer across Medicaid, Medicare, and commercial segments
Anthem — Major managed care insurer with significant Medicaid and Marketplace presence
Humana — Focused health insurer with strong Medicare Advantage and Medicaid operations
Aetna — Integrated health insurer with diverse government and commercial programs
Recent Developments
(Feb 2026) Q4 2025 earnings miss with adjusted loss guidance; stock dropped 29.88% in premarket
(Feb 2026) Multiple analyst downgrades; Goldman Sachs lowered price target to $124, Deutsche Bank to $109
(Feb 2026) Strategic announcement to exit Medicare Advantage by 2027 and refocus on Medicaid and Marketplace segments
Open the full interactive Molina Healthcare, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.